Skip to main content
    B

    BridgeBio Pharma Inc (BBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $67.13
    +2.19 (+3.37%)

    Market Cap: $12.70B

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    28%(8/29)
    Avg Surprise
    -10.33%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.63
    Range$-0.87 - $-0.40
    7 analysts
    EPS RevisionsNo revisions (7d)
    0
    7
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.47-33.7%
    60d ago$-0.49-27.5%
    30d ago$-0.63+0.4%
    7d ago$-0.63+0.4%
    Current$-0.63
    Revenue Consensus
    $270M
    Range$254M - $295M
    17 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.76
    Range$-1.08 - $-0.05
    8 analysts
    Revenue Consensus
    $358M
    Range$296M - $450M
    19 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.76---
    Sep 26EST
    		-$-0.63---
    Jun 26
    Reported Aug 10
    		$-0.78$-0.64-21.88%Miss+17.9%
    Mar 26
    Reported May 7
    		$-0.84$-0.62-35.48%Miss+15.0%
    Dec 25
    Reported Feb 24
    		$-0.94$-0.72-31.13%Miss+31.7%
    Sep 25
    Reported Oct 29
    		$-0.72$-0.78+7.69%Beat+16.2%
    Jun 25
    Reported Aug 5
    		$-0.95$-0.60-58.33%Miss+5.9%
    Mar 25
    Reported Apr 29
    		$-0.99$-0.89-11.10%Miss-724.0%
    Dec 24
    Reported Feb 20
    		$-1.37$-1.09-26.09%Miss-43.2%
    Sep 24
    Reported Nov 12
    		$-0.86$-0.98+12.29%Beat+20.4%
    Jun 24
    Reported Aug 1
    		$-1.01$-0.94-7.45%Miss-5.2%
    Mar 24
    Reported May 2
    		$-0.12N/A+77.78%Beat+86.7%
    Dec 23
    Reported Feb 22
    		$-0.96$-0.91-5.49%Miss-4.3%
    Sep 23
    Reported Nov 2
    		$-1.08$-0.89-21.35%Miss-21.3%
    Jun 23
    Reported Aug 3
    		$-0.96$-0.87-10.34%Miss-28.0%
    Mar 23
    Reported May 4
    		$-0.90$-0.83-8.43%Miss+24.4%
    Dec 22
    Reported Feb 23
    		$-0.92$-0.85-8.24%Miss+8.9%
    Sep 22
    Reported Nov 3
    		$-0.89$-1.01+11.88%Beat+16.0%
    Jun 22
    Reported Aug 4
    		$-0.75$-0.86+12.79%Beat-13.6%
    Mar 22
    Reported May 5
    		$-1.19$-1.10-8.18%Miss-0.8%
    Dec 21
    Reported Feb 24
    		$-1.01$-0.87-16.09%Miss+0.0%
    Sep 21
    Reported Nov 4
    		$-1.06$-0.91-16.48%Miss-8.2%
    Jun 21
    Reported Aug 5
    		$-0.66$-0.89+25.84%Beat+35.9%
    Mar 21
    Reported May 6
    		$-1.18$-0.75-57.33%Miss-51.3%
    Dec 20
    Reported Feb 25
    		$-1.01$-0.85-18.82%Miss-62.9%
    Sep 20
    Reported Nov 5
    		$-0.98$-0.89-10.11%Miss-92.2%
    Jun 20
    Reported Aug 11
    		$-1.03$-0.73-41.10%Miss-83.9%
    Mar 20
    Reported May 13
    		$-0.78$-0.70-11.43%Miss+76.0%
    Dec 19
    Reported Mar 2
    		$-0.62$-0.70+11.43%Beat-
    Sep 19
    Reported Nov 7
    		$-0.51$-0.54+5.56%Beat-
    Jun 19
    Reported Aug 14
    		$-0.56$-0.40-40.00%Miss-
    Mar 19
    Reported Jun 28
    		$-3.25$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-20.47EV/EBITDAN/A
    Price/FCF-30.19xFCF Yield-3.31%
    Profitability
    Profit Margin-97.00%Operating Margin-43.90%
    ROE-1790.00%ROIC914.10%
    Financial Health
    Debt/Equity-0.98xInterest Coverage-2.23x
    Current Ratio1.23xQuick Ratio1.17x
    Trading Statistics
    Beta0.97Avg Volume3.04M
    52-Week High$93.4252-Week Low$52.75

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$65.84
    SMA 20$66.18
    SMA 50$73.27
    SMA 200$73.13
    EMA 10$65.84
    EMA 20$67.07
    EMA 50$70.82
    EMA 200$70.45

    MACD

    Line: -1.99Signal: -2.40Hist: 0.41

    ADX

    ADX: 29.9+DI: 16.1-DI: 24.1

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$67.85

    Bollinger Bands

    Upper Band$68.52
    Lower Band$63.85
    %B Position706%(Upper)
    Band Width0.70

    RSI (14-Day)

    Neutral
    46.6

    Momentum Oscillators

    Stoch %K38.5
    Stoch %D28.3
    Williams %R-26.6
    ROC (10d)0.3%
    Momentum0.22
    CCI (20d)48.9
    MFI (14d)66.2

    Volatility Measures

    ATR (14d)$2.41(3.6%)
    StdDev (20d)1.17
    Hist Vol35.2%(Moderate)

    Volume Flow

    VWAP$66.78
    OBV50.6M
    AD Line-4.6M
    CMF (20d)-0.072

    Volume Metrics

    Avg Vol (20d)3.0M
    Vol Ratio0.9x
    VWMA (20d)$66.27

    Pivot Points

    R3$68.41
    R2$66.89
    R1$65.91
    Pivot Point$64.39
    S1$63.41
    S2$61.89
    S3$60.91

    Advanced Oscillators

    TSI-27.51
    Ultimate Osc49.0
    KST-103.84

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$243.68M$194.51M$154.18M$120.70M$110.56M$116.63M$3.71M$2.73M$4.34M$211.12M$1.75M$4.09M
    Cost of Revenue$15.05M$9.94M$8.11M$6.56M$3.65M$2.64M$1.49M$598,000$1.20M$598,000$598,000$598,000
    Gross Profit$228.63M$184.58M$146.07M$114.14M$106.91M$113.99M$2.23M$2.13M$3.14M$210.52M$1.15M$3.49M
    Operating Expenses$335.71M$290.53M$285.63M$259.34M$241.19M$218.37M$229.82M$193.88M$177.11M$210.18M$178.56M$161.19M
    R&D$149.45M$126.64M$116.42M$112.87M$111.23M$111.43M$130.35M$120.44M$114.69M$140.97M$130.23M$125.14M
    SG&A$186.26M$163.90M$158.09M$137.62M$129.15M$106.36M$94.78M$68.82M$59.52M$65.81M$47.58M$35.78M
    Operating Income$-107,079,000$-105,956,000$-139,562,000$-145,199,000$-134,278,000$-104,372,000$-226,027,000$-191,750,000$-175,539,000$343,000$-177,416,000$-157,692,000
    Interest Income$224,000$-12,037,000$-16,697,000$-9,595,000$-16,291,000$-10,171,000$-12,012,000$48.76M$123.56M$4.08M$5.58M$3.79M
    Interest Expense$54.62M$52.81M$50.31M$48.15M$37.64M$63.30M$29.82M$23.06M$22.94M$50.06M$20.27M$20.31M
    Income Before Tax$-155,891,000$-166,555,000$-194,755,000$-186,482,000$-181,658,000$-169,608,000$-266,236,000$-164,254,000$-75,544,000$-36,160,000$-170,328,000$-179,488,000
    Income Tax Expense$0$0$0$-1,545,000$2.10M$0$0$0$0$0$0$0
    Net Income$-155,891,000$-166,555,000$-194,635,000$-184,937,000$-183,758,000$-169,608,000$-267,389,000$-164,254,000$-75,544,000$-36,160,000$-170,328,000$-179,488,000
    EBITDA$-98,513,000$-98,698,000$-124,857,000$-127,340,000$-124,978,000$-93,236,000$-226,290,000$-188,415,000$-174,597,000$11.42M$-154,053,000$-161,336,000
    EBIT$-101,492,000$-101,703,000$-127,744,000$-128,738,000$-127,730,000$-96,141,000$-224,403,000$-189,953,000$-176,171,000$9.83M$-155,638,000$-162,975,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BBIO

    News

    BBIO Assumes Buy Rating by UBS -- Price Target Raised to $92.00

    UBS has initiated a Buy rating for BridgeBio Pharma (BBIO) and increased its price target to $92.00, reflecting a positive outlook on the company's advancements in genetic disease treatments. Despite this positive...

    GuruFocus•10/15/26•Bullish

    UBS sets USD 92.00 target for BridgeBio Pharma stock

    UBS has set a Buy rating and a $92.00 price target for BridgeBio Pharma (BBIO), indicating a potential 36.86% upside from its current Nasdaq quote. The company reported strong Q2 2026 revenue of $243.68 million and is...

    ad-hoc-news.de•10/15/26•Bullish

    H.C. Wainwright reiterates Buy on BridgeBio stock, cites trial data

    H.C. Wainwright has reiterated a Buy rating and a $120.00 price target for BridgeBio Pharma (NASDAQ:BBIO) after the company presented positive Phase 3 clinical trial data for encaleret at a medical conference. The data...

    Investing.com•10/15/26•Bullish

    BridgeBio Pharma Inc. (US10806X1028.SG) recent insider transactions

    This article provides an overview of recent insider transaction data for BridgeBio Pharma Inc. (US10806X1028.SG). It details insider purchases and sales over the last six months...

    Yahoo Finance UK•10/14/26•Neutral

    Should Late Stage Pipeline Progress Require Action From BridgeBio Pharma (BBIO) Investors?

    BridgeBio Pharma has announced positive clinical trial data and regulatory milestones across several late-stage programs, including acoramidis, encaleret...

    Simply Wall Street•10/14/26•Somewhat-Bullish

    BBIO Valuation and Fair Value

    P/E
    -20.5x
    P/FCF
    -30.2x
    P/B
    -5.2x
    See GNG's fair value

    BBIO Profitability: Margins, ROIC and FCF

    Gross margin
    94.4%
    Operating margin
    -43.9%
    Net margin
    -97.0%
    ROIC
    914.1%
    ROE
    -1790.0%
    FCF margin
    -61.1%
    FCF yield
    -3.3%

    BBIO Competitors

    CompanyTicker
    Baxter International IncBAX
    Penumbra IncPEN
    Summit Therapeutics PLCSMMT
    BrightSpring Health Services, Inc. Common StockBTSG
    ICON PLCICLR
    Encompass Health CorpEHC
    Halozyme Therapeutics IncHALO
    Tempus AI, Inc. Class A Common StockTEM

    Sector: Healthcare

    BBIO Analyst Ratings

    Consensus
    Buy
    Analysts
    22
    Strong Buy
    5
    Buy
    14
    Hold
    3
    Sell
    0
    Strong Sell
    0

    BBIO Bull Case vs Bear Case

    Bull case

    • BBIO earns a 914.1% return on invested capital.
    • BBIO grew quarterly revenue 120.4% year over year.
    • 86.4% of BBIO's analyst ratings are Buy or Strong Buy.

    Bear case

    • BBIO has a -97.0% net profit margin.
    • BBIO beat EPS estimates in 25.0% of its last 8 reported quarters.

    BBIO Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -20.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.63
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 7 down

    Frequently Asked Questions About BBIO

    Does BBIO pay dividends?

    BridgeBio Pharma Inc (BBIO) does not currently pay a regular dividend.

    What is BBIO's market cap?

    BridgeBio Pharma Inc (BBIO) has a market capitalization of $12.70B with a current stock price of $67.13.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In